Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning vs Evening Travoprost/Timolol in Glaucoma
NCT00051194Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Sep 2002
- Primary completion
- Jul 2003
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of travoprost and timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Mean Intraocular Pressure at 6 weeks. Started Sep 2002; status: completed.
02
Drugs
travoprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00051194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051194.